trial

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

NCTId NCT05654870
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 8 (actual)
Sponsored by Neurocrine Biosciences
Primary completion 2023-11-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
8 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2023-01-05
Primary completion
2023-11-08
Eligibility
ALL · 13 Years

Interventions & indications

Drugs
Valbenazine

Sponsors

Neurocrine BiosciencesLead Sponsor

Investigators

1
Clinical Development LeadStudy Director

Sites

3 total
San Jose, United StatesCoral Gables, United StatesAtlanta, United States

Linked catalysts

1
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Ad — primary completion2023-11-08

Facts & assertions

4 sourced
Enrollment
8
Phase
PHASE3
Primary Completion Date
2023-11-08
Status
TERMINATED
relationships
The graph out of here
drug
Valbenazine
drug
lead_sponsor
Neurocrine Biosciences
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Clinical Development Lead
person